CD274 and neoplasm: Considering that strong PD‐L1 stabilization was evident in UCD52 mixed TNBC PDX tumors (Fig 1K and L) and that all human tumors are heterogeneous and given that all tested DR5 agonists have failed in clinical trials, a scenario can be envisioned where surface stabilized PD‐L1 on dying (highly DR5 sensitive) tumor cells influences the function of neighboring non‐dying cells (not DR5 sensitive) having cytotoxicity below apoptotic threshold (Fig 3A).